{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:41:14Z","timestamp":1793421674219,"version":"4.5.0"},"reference-count":54,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"the third round of public welfare development and reform pilot projects of Beijing Municipal Medical Research Institutes","award":["Beijing Medical Research Institute, 2019-1"],"award-info":[{"award-number":["Beijing Medical Research Institute, 2019-1"]}]},{"name":"X-Young Scholars Project","award":["PKU2021LCXQ016"],"award-info":[{"award-number":["PKU2021LCXQ016"]}]},{"name":"the Key Program of Beijing Natural Science Foundation","award":["No. Z210015"],"award-info":[{"award-number":["No. Z210015"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,1,31]]},"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Epstein-Barr virus (EBV)-associated gastric cancer (GC) (EBVaGC) is a distinct molecular subtype of GC with a favorable prognosis. However, the exact effects and potential mechanisms of EBV infection on immune checkpoint blockade (ICB) efficacy in GC remain to be clarified. Additionally, EBV-encoded RNA (EBER) in situ hybridization (ISH), the traditional method to detect EBV, could cause false-positive\/false-negative results and not allow for characterizing other molecular biomarkers recommended by standard treatment guidelines for GC. Herein, we sought to investigate the efficacy and potential biomarkers of ICB in EBVaGC identified by next-generation sequencing (NGS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>An NGS-based algorithm for detecting EBV was established and validated using two independent GC cohorts (124 in the training cohort and 76 in the validation cohort). The value of EBV infection for predicting ICB efficacy was evaluated among 95 patients with advanced or metastatic GC receiving ICB. The molecular predictive biomarkers for ICB efficacy were identified to improve the prediction accuracy of ICB efficacy in 22 patients with EBVaGC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared with orthogonal assay (EBER-ISH) results, the NGS-based algorithm achieved high performance with a sensitivity of 95.7% (22\/23) and a specificity of 100% (53\/53). EBV status was identified as an independent predictive factor for overall survival and progression-free survival in patients with DNA mismatch repair proficient (pMMR) GC following ICB. Moreover, the patients with EBV+\/pMMR and EBV\u2212\/MMR deficient (dMMR) had comparable and favorable survival following ICB. Twenty-two patients with EBV+\/pMMR achieved an objective response rate of 54.5% (12\/22) on immunotherapy. Patients with EBVaGC with a high cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) level were less responsive to anti-programmed death-1\/ligand 1 (PD-1\/L1) monotherapy, and the combination of anti-CTLA-4 plus anti-PD-1\/L1 checkpoint blockade benefited patients with EBVaGC more than anti-PD-1\/L1 monotherapy with a trend close to significance (p=0.074). There were nearly significant differences in tumor mutational burden (TMB) level and\n                      <jats:italic>SMARCA4<\/jats:italic>\n                      mutation frequency between the ICB response and non-response group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      We developed an efficient NGS-based EBV detection strategy, and this strategy-identified EBV infection was as effective as dMMR in predicting ICB efficacy in GC. Additionally, we identified CTLA-4, TMB, and\n                      <jats:italic>SMARCA4<\/jats:italic>\n                      mutation as potential predictive biomarkers of ICB efficacy in EBVaGC, which might better inform ICB treatment for EBVaGC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2021-004080","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T11:07:42Z","timestamp":1646305662000},"page":"e004080","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":109,"title":["Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer"],"prefix":"10.1136","volume":"10","author":[{"given":"Yuezong","family":"Bai","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Tong","sequence":"additional","affiliation":[{"name":"Medical Affairs, 3D Medicines, Inc, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Zhao","sequence":"additional","affiliation":[{"name":"Medical Affairs, 3D Medicines, Inc, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feilong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Medical Affairs, 3D Medicines, Inc, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Cai","sequence":"additional","affiliation":[{"name":"Medical Affairs, 3D Medicines, Inc, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1134-2922","authenticated-orcid":false,"given":"Lin","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"key":"2025100309565815000_10.3.e004080.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2009.05775.x"},{"key":"2025100309565815000_10.3.e004080.2","doi-asserted-by":"publisher","DOI":"10.1038\/nature13480"},{"key":"2025100309565815000_10.3.e004080.3","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ijc.32490","article-title":"Prospective observation: clinical utility of plasma Epstein-Barr virus DNA load in ebv-associated gastric carcinoma patients","volume":"146","author":"Qiu","year":"2020","journal-title":"Int J Cancer"},{"key":"2025100309565815000_10.3.e004080.4","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00955-13"},{"key":"2025100309565815000_10.3.e004080.5","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000176428.06629.1e"},{"key":"2025100309565815000_10.3.e004080.6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.gastro.2010.04.002","article-title":"Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma","volume":"139","author":"Song","year":"2010","journal-title":"Gastroenterology"},{"key":"2025100309565815000_10.3.e004080.7","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1813-9","article-title":"Prognostic significance of Epstein-Barr virus infection in gastric cancer: a meta-analysis","volume":"15","author":"Liu","year":"2015","journal-title":"BMC Cancer"},{"key":"2025100309565815000_10.3.e004080.8","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920937434","article-title":"Observational cohort study of clinical outcome in Epstein-Barr virus associated gastric cancer patients","volume":"12","author":"Qiu","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"2025100309565815000_10.3.e004080.9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0075"},{"key":"2025100309565815000_10.3.e004080.10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz197"},{"key":"2025100309565815000_10.3.e004080.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0101-z"},{"key":"2025100309565815000_10.3.e004080.12","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s10120-015-0508-x","article-title":"Validation and calibration of next-generation sequencing to identify Epstein-Barr virus-positive gastric cancer in the cancer genome atlas","volume":"19","author":"Camargo","year":"2016","journal-title":"Gastric Cancer"},{"key":"2025100309565815000_10.3.e004080.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-1578(10)60642-3"},{"key":"2025100309565815000_10.3.e004080.14","unstructured":"(NCCN) NCCN . NCCN clinical practice Guildline in oncology. Gastric Cancer 2021."},{"key":"2025100309565815000_10.3.e004080.15","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00823-11"},{"key":"2025100309565815000_10.3.e004080.16","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1099\/jmm.0.000839","article-title":"Determination and genome-wide analysis of Epstein-Barr virus (EBV) sequences in ebv-associated gastric carcinoma from Guangdong, an endemic area of nasopharyngeal carcinoma","volume":"67","author":"Chen","year":"2018","journal-title":"J Med Microbiol"},{"key":"2025100309565815000_10.3.e004080.17","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L"},{"key":"2025100309565815000_10.3.e004080.18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF01407318","article-title":"Biosafety procedures in cell culture","volume":"11","author":"Caputo","year":"1988","journal-title":"Journal of Tissue Culture Methods"},{"key":"2025100309565815000_10.3.e004080.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2003.08.007"},{"key":"2025100309565815000_10.3.e004080.20","doi-asserted-by":"crossref","DOI":"10.1186\/2042-4280-5-1","article-title":"Epstein-Barr virus IL-10 gene expression by a recombinant murine gammaherpesvirus in vivo enhances acute pathogenicity but does not affect latency or reactivation","volume":"5","author":"Lindquester","year":"2014","journal-title":"Herpesviridae"},{"key":"2025100309565815000_10.3.e004080.21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.meegid.2018.07.022","article-title":"Recombination rates along the entire Epstein Barr virus genome display a highly heterogeneous landscape","volume":"65","author":"Berenstein","year":"2018","journal-title":"Infect Genet Evol"},{"key":"2025100309565815000_10.3.e004080.22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","article-title":"Epstein-Barr virus and cancer","volume":"14","author":"Farrell","year":"2019","journal-title":"Annu Rev Pathol"},{"key":"2025100309565815000_10.3.e004080.23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00265"},{"key":"2025100309565815000_10.3.e004080.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.6212"},{"key":"2025100309565815000_10.3.e004080.25","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-018-0836-8"},{"key":"2025100309565815000_10.3.e004080.26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1825"},{"key":"2025100309565815000_10.3.e004080.27","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2017.1286985"},{"key":"2025100309565815000_10.3.e004080.28","doi-asserted-by":"crossref","first-page":"9.e1","DOI":"10.1016\/j.humpath.2007.05.024","article-title":"Recommendations for the reporting of gastric carcinoma","volume":"39","author":"Robert","year":"2008","journal-title":"Hum Pathol"},{"key":"2025100309565815000_10.3.e004080.29","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i26.2818"},{"key":"2025100309565815000_10.3.e004080.30","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21338"},{"key":"2025100309565815000_10.3.e004080.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31827-5"},{"key":"2025100309565815000_10.3.e004080.32","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025100309565815000_10.3.e004080.33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00175-3"},{"key":"2025100309565815000_10.3.e004080.34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02105"},{"key":"2025100309565815000_10.3.e004080.35","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.immuni.2021.03.012","article-title":"Clonal multi-omics reveals BCOR as a negative regulator of emergency dendritic cell development","volume":"54","author":"Tian","year":"2021","journal-title":"Immunity"},{"key":"2025100309565815000_10.3.e004080.36","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.annonc.2020.04.011","article-title":"Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas","volume":"31","author":"Derks","year":"2020","journal-title":"Ann Oncol"},{"key":"2025100309565815000_10.3.e004080.37","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx213"},{"key":"2025100309565815000_10.3.e004080.38","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5256.1734"},{"key":"2025100309565815000_10.3.e004080.39","doi-asserted-by":"crossref","unstructured":"Solinas C , De Silva P , Bron D . Significance of Tim3 expression in cancer: from biology to the clinic. Paper presented at: Seminars in oncology, 2019.","DOI":"10.1053\/j.seminoncol.2019.08.005"},{"key":"2025100309565815000_10.3.e004080.40","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000497"},{"key":"2025100309565815000_10.3.e004080.41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41416-021-01607-3","article-title":"TIM3+ cells in gastric cancer: clinical correlates and association with immune context","volume":"126","author":"Chen","year":"2022","journal-title":"Br J Cancer"},{"key":"2025100309565815000_10.3.e004080.42","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-020-01151-8"},{"key":"2025100309565815000_10.3.e004080.43","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/1759-7714.13215","article-title":"Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: a case report","volume":"10","author":"Takada","year":"2019","journal-title":"Thorac Cancer"},{"key":"2025100309565815000_10.3.e004080.44","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/annonc\/mdz160","article-title":"Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor","volume":"30","author":"Henon","year":"2019","journal-title":"Ann Oncol"},{"key":"2025100309565815000_10.3.e004080.45","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10902-w","article-title":"The genomic landscape of Epstein-Barr virus-associated pulmonary Lymphoepithelioma-like carcinoma","volume":"10","author":"Hong","year":"2019","journal-title":"Nat Commun"},{"key":"2025100309565815000_10.3.e004080.46","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jhep.2020.10.037","article-title":"Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma","volume":"74","author":"Huang","year":"2021","journal-title":"J Hepatol"},{"key":"2025100309565815000_10.3.e004080.47","doi-asserted-by":"crossref","first-page":"32925","DOI":"10.18632\/oncotarget.9076","article-title":"Abundant PD-L1 expression in Epstein-Barr virus-infected gastric cancers","volume":"7","author":"Derks","year":"2016","journal-title":"Oncotarget"},{"key":"2025100309565815000_10.3.e004080.48","doi-asserted-by":"publisher","DOI":"10.1038\/ng.982"},{"key":"2025100309565815000_10.3.e004080.49","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/annonc\/mdx047","article-title":"Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations","volume":"28","author":"B\u00f6ger","year":"2017","journal-title":"Ann Oncol"},{"key":"2025100309565815000_10.3.e004080.50","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01022-18","article-title":"Epstein-Barr virus microRNA miR-BART5-3p inhibits p53 expression","volume":"92","author":"Zheng","year":"2018","journal-title":"J Virol"},{"key":"2025100309565815000_10.3.e004080.51","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1581556","article-title":"Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer","volume":"8","author":"Borcoman","year":"2019","journal-title":"Oncoimmunology"},{"key":"2025100309565815000_10.3.e004080.52","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.canlet.2020.01.001","article-title":"ARID1A deficiency and immune checkpoint blockade therapy: from mechanisms to clinical application","volume":"473","author":"Hu","year":"2020","journal-title":"Cancer Lett"},{"key":"2025100309565815000_10.3.e004080.53","doi-asserted-by":"crossref","first-page":"11466","DOI":"10.18632\/aging.103231","article-title":"Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma","volume":"12","author":"Jiang","year":"2020","journal-title":"Aging"},{"key":"2025100309565815000_10.3.e004080.54","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.annonc.2021.03.203","article-title":"Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in Ras-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy","volume":"32","author":"Wang","year":"2021","journal-title":"Ann Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-004080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:57:06Z","timestamp":1759510626000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-004080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":54,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,3]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/jitc-2021-004080"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-004080","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}